/OKUR
OKUR Stock - OnKure Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$3.01-3.22%
$0.10 (-3.22%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.56
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1062.8%upside
Target: $35.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for OKUR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.98 – $3.04
TARGET (TP)$35.00
STOP LOSS$2.77
RISK/REWARD1:133.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.47
52W High$9.40
52W Low$1.70
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | $-50,000 | $-37,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-54,386,000 | $-36,934,000 | $-29,766,000 | $-39,818,000 | $-19,552,000 |
| Net Income | $-52,673,000 | $-35,311,000 | $-29,512,000 | $-39,770,000 | $-19,465,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.95 | $-2.65 | $-2.21 | $-21.92 | $-7.74 |
Company Overview
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$34
Average Target
↑ 1029.6% Upside
Now
$33
Low
$34
Average
$35
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 30th 2025 | Evercore ISI | Initiation | Outperform | - |
| December 5th 2024 | Leerink Partners | Initiation | Outperform | $33 |
| October 10th 2024 | Oppenheimer | Initiation | Outperform | $35 |
Earnings History & Surprises
OKURBeat Rate
69%
Last 13 quarters
Avg Surprise
+13.0%
EPS vs Estimate
Beats / Misses
9/4
Last 12 quarters
Latest EPS
$-1.09
Q4 2025
EPS Surprise History
Q4 23
-21.1%
$-7.00vs$-5.78
Q2 24
+32.4%
$-0.25vs$-0.37
Q3 24
-60.0%
$-1.60vs$-1.00
Q4 24
-13.4%
$-1.10vs$-0.97
Q1 25
-59.3%
$-1.37vs$-0.86
Q2 25
+9.8%
$-1.19vs$-1.32
Q3 25
+7.3%
$-1.14vs$-1.23
Q4 25
+9.2%
$-1.09vs$-1.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Mar 9, 2026 | $-1.15 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.20 | $-1.09 | +9.2% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-1.23 | $-1.14 | +7.3% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-1.32 | $-1.19 | +9.8% | ✓ BEAT |
Q1 2025 | Mar 10, 2025 | $-0.86 | $-1.37 | -59.3% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.97 | $-1.10 | -13.4% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-1.00 | $-1.60 | -60.0% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.37 | $-0.25 | +32.4% | ✓ BEAT |
Q4 2023 | Dec 31, 2023 | $-5.78 | $-7.00 | -21.1% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $-5.71 | $-1.44 | +74.8% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-5.30 | $-0.61 | +88.4% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-6.04 | $-0.65 | +89.2% | ✓ BEAT |
Q1 2023 | Mar 27, 2023 | $-5.88 | $-5.60 | +4.8% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-5.72 | $-5.30 | +7.3% | ✓ BEAT |
Frequently Asked Questions about OKUR
What is OKUR's current stock price?
OnKure Therapeutics, Inc. (OKUR) is currently trading at $3.01 per share. The stock has moved -3.22% today.
What is the analyst price target for OKUR?
The average analyst price target for OKUR is $35.00, based on 1 analyst.
What sector is OnKure Therapeutics, Inc. in?
OnKure Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is OKUR's market cap?
OnKure Therapeutics, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does OKUR pay dividends?
No, OnKure Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGS
Aligos Therapeutics, Inc.
$10.68
Mkt Cap: $0.1B
ATNM
Actinium Pharmaceuticals, Inc.
$1.69
Mkt Cap: $0.1B
BRNS
Barinthus Biotherapeutics plc
$0.74
Mkt Cap: $0.0B
CVM
CEL-SCI Corporation
$4.91
Mkt Cap: $0.0B
FGEN
FibroGen, Inc.
$8.60
Mkt Cap: $0.0B
KZR
Kezar Life Sciences, Inc.
$6.34
Mkt Cap: $0.0B
MRSN
Mersana Therapeutics, Inc.
$28.94
Mkt Cap: $0.1B
PDSB
PDS Biotechnology Corporation
$0.89
Mkt Cap: $0.0B
TPST
Tempest Therapeutics, Inc.
$3.12
Mkt Cap: $0.0B
XLO
Xilio Therapeutics, Inc.
$0.67
Mkt Cap: $0.0B
Explore stocks similar to OKUR for comparison